General information, events and/or links.




May 24, 2016

New publication on cell-free miRNA in prostate cancer

"Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review."

by Endzeliņš E(1), Melne V(1,)(2), Kalniņa Z(1), Lietuvietis V(1,)(2), Riekstiņa
U(3), Llorente A(4), Linē A(5). PMCID: PMC4870749 PMID: 27189160  [PubMed - in process]

Author information:
(1)Latvian Biomedical Research and Study Centre, Ratsupites Str 1, k-1, LV-1067,
Riga, Latvia. (2)Riga Stradiņš University, Dzirciema Str 16, Riga, LV-1007,
Latvia. (3)Faculty of Medicine, University of Latvia, 19 Raina blvd., Riga,
LV-1586, Latvia. (4)Department of Molecular Cell Biology, Institute for Cancer
Research, Oslo University Hospital-The Norwegian Radium Hospital, 0379, Oslo,
Norway. (5)Latvian Biomedical Research and Study Centre, Ratsupites Str 1, k-1,
LV-1067, Riga, Latvia.



Prostate cancer, the second most frequently diagnosed cancer in males worldwide,
is estimated to be diagnosed in 1.1 million men per year. Introduction of PSA
testing substantially improved early detection of prostate cancer, however it
also led to overdiagnosis and subsequent overtreatment of patients with an
indolent disease. Treatment outcome and management of prostate cancer could be
improved by the development of non-invasive biomarker assays that aid in
increasing the sensitivity and specificity of prostate cancer screening, help to
distinguish aggressive from indolent disease and guide therapeutic decisions.
Prostate cancer cells release miRNAs into the bloodstream, where they exist
incorporated into ribonucleoprotein complexes or extracellular vesicles. Later,
cell-free miRNAs have been found in various other biofluids. The initial RNA
sequencing studies suggested that most of the circulating cell-free miRNAs in
healthy individuals are derived from blood cells, while specific
disease-associated miRNA signatures may appear in the circulation of patients
affected with various diseases, including cancer. This raised a hope that
cell-free miRNAs may serve as non-invasive biomarkers for prostate cancer.
Indeed, a number of cell-free miRNAs that potentially may serve as diagnostic,
prognostic or predictive biomarkers have been discovered in blood or other
biofluids of prostate cancer patients and need to be validated in appropriately
designed longitudinal studies and clinical trials. In this review, we
systematically summarise studies investigating cell-free miRNAs in biofluids of
prostate cancer patients and discuss the utility of the identified biomarkers in
various clinical scenarios. Furthermore, we discuss the possible mechanisms of
miRNA release into biofluids and outline the biological questions and technical
challenges that have arisen from these studies.


The article in available from pubmed in full text here.

Previous page: EVents  Next page: Newsletter